News

Tevard Biosciences Announces Publication of Preclinical Research Supporting Engineered Suppressor tRNAs for Duchenne Muscular Dystrophy

Read more

Tevard Biosciences Presents Preclinical Data Showing Complete Dystrophin Restoration and Robust Titin Rescue with Suppressor tRNA Therapy at ASGCT 2026

Read more

Suppressor tRNAs: Giving genetic medicines a broader reach

Read more

Suppressor tRNAs as personalized therapy for nonsense mutation-associated pathologies

Read more

Tevard Biosciences Presents Data Showing Compelling Full-Length Protein Rescue with tRNA-based Treatment for Duchenne Muscular Dystrophy and Dilated Cardiomyopathy at the 2025 FEBS Special Meeting

Read more

Rescue of Full-Length Dystrophin Protein in a Mouse Model of Duchenne Muscular Dystrophy Using an AAV-tRNA Therapeutic

Read more

Tevard Biosciences Names Dr. Elisabeth Gardiner Chief Scientific Officer to Lead Next Phase of tRNA-Based Therapies

Read more

Tevard Reports Data on Suppressor tRNA Therapy Restoring Full-Length Dystrophin in Duchenne Muscular Dystrophy Model

Read more

Tevard to Present Data Demonstrating tRNA-based Therapy Rescued Full-Length Dystrophin and Motor Function in Duchenne Muscular Dystrophy Model

Read more

Tevard Biosciences to Move Corporate Headquarters to Lilly Gateway Labs in Boston’s Seaport

Read more